Stryker CORP 10-Q quarterly reports

Stryker Corporation announced a 9.4% increase in net sales for the second quarter of 2026, reaching $6,589 million, driven by robust performance across its MedSurg and Orthopaedics segments.

Stryker Corporation announced its first quarter 2026 financial results, with net sales increasing by 2.6% to $6.02 billion, driven by higher unit volumes across key segments.

Stryker Corporation reported a 10.3% increase in net sales for the third quarter of 2025, driven by strong unit volume and the strategic acquisition of Inari Medical.

Stryker Corporation announced robust sales growth for the second quarter and first half of 2025, driven by strong organic performance and strategic acquisitions, despite a decline in GAAP net earnings for the six-month period due to integration costs and impairments.

Stryker Corporation's Q1 2025 results show an 11.9% increase in sales, driven by the acquisition of Inari Medical and strong organic growth, though net earnings per diluted share decreased.

Stryker Corporation's third-quarter results show a significant increase in sales and earnings, driven by higher unit volume across its MedSurg and Neurotechnology and Orthopaedics and Spine segments.

Stryker Corporation achieved a robust 8.5% sales growth in the second quarter of 2024, with significant contributions from its MedSurg and Neurotechnology segment.

Stryker Corporation's first quarter 2024 results show a robust 9.7% increase in net sales, driven by strong performance across both MedSurg and Neurotechnology and Orthopaedics and Spine segments.